Top Markets
Coin of the day
Myovant Sciences Ltd. Myovant Sciences Ltd.

Myovant Sciences Ltd.

MYOV
Rang in Aktien #5521
Myovant Sciences Ltd. is a biopharmaceutical company focused on innovating... Myovant Sciences Ltd. is a biopharmaceutical company focused on innovating healthcare solutions for both women and men. Its flagship product is relugolix, an orally administered, once-daily small molecule that functions as a gonadotropin-releasing hormone (GnRH) receptor antagonist. This medication is indicated for conditions such as heavy menstrual bleeding caused by uterine fibroids, pain associated with endometriosis, and advanced prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin agonist, currently in Phase II clinical trials for treating female infertility within assisted reproductive procedures. Myovant collaborates with Pfizer Inc. for the development and commercialization of relugolix across oncology and women's health sectors. Incorporated in 2016, initially as Roivant Endocrinology Ltd. before rebranding to Myovant Sciences Ltd. in May of that year, the firm is based in London, United Kingdom, and operates as a subsidiary of Sumitovant Biopharma Ltd.
Aktienkurs
$26.98
Zuletzt synchronisiert: 2023-03-09
Marktkapitalisierung
$2.62B
Veränderung (1 Tag)
-0.04%
Veränderung (1 Jahr)
0.00%
Land
GB
Handel Myovant Sciences Ltd. (MYOV)

Kategorie

Kursverlauf für Myovant Sciences Ltd. (MYOV)
Höchster Schlusskurs: $26.97 am 2023-03-01

Niedrigster Schlusskurs: $12.79 am 2016-10-01
Kursverlauf der Aktie von Myovant Sciences Ltd. von 2016 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2023 0.28%
2022 73.07%
2021 -37.07%
2020 50.47%
2019 -4.83%
2018 41.15%
2017 8.58%
2016 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$549.38 41.20%
US
$1.05K 47.75%
NL
$148.35 491.02%
US
$122.63 -12.65%
AU
$762.91 6.87%
CH